Changeflow GovPing Pharma & Drug Safety Patent Application: Compounds for Inhibiting IL-17
Routine Notice Added Draft

Patent Application: Compounds for Inhibiting IL-17

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260083708A1) detailing compounds for inhibiting IL-17 activity. The application, filed on December 1, 2025, describes compounds and methods for treating inflammatory and autoimmune disorders.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO detailing novel compounds designed to inhibit or regulate the activity of Interleukin-17 (IL-17). The application, identified as US20260083708A1, includes specific chemical structures (Formula I) and outlines methods for treating inflammatory and autoimmune diseases. The filing date was December 1, 2025.

As this is a patent application, it represents a disclosure of potential new intellectual property rather than a regulatory mandate. Companies in the pharmaceutical and biotechnology sectors involved in the research and development of treatments for inflammatory and autoimmune disorders may find this application relevant for competitive intelligence and potential licensing opportunities. There are no immediate compliance obligations or deadlines associated with this publication.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

IL-17 MODULATORS AND USES THEREOF

Application US20260083708A1 Kind: A1 Mar 26, 2026

Inventors

Yucheng PANG, Feiyang XU, Xiangyang CHEN

Abstract

The present invention relates to compounds suitable for inhibiting or regulating the activity of IL-17. The present invention is directed to compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof. The present invention further relates to methods for treating and/or preventing various human diseases, including inflammatory and autoimmune disorders. The present invention also provides methods for preparing the compounds of the present invention.

CPC Classifications

A61K 31/4196 A61P 19/02 C07D 401/10

Filing Date

2025-12-01

Application No.

19405049

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
December 1st, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083708A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Drug Labeling
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!